Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV21 Vaccine in Healthy Infants and Toddlers
NCT06975878Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2025
- Primary completion
- Aug 2027
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of PCV21 in pneumococcal infection, sponsored by Sanofi. Primary endpoints: Seroresponse rate for PCV21 and 15vPCV serotypes and IgG concentration for PCV21 and 15vPCV serotypes. Started May 2025; status: active, not recruiting.
02
Drugs
PCV21
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06975878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975878.